The FDA approval of tafasitamab with R-squared for R/R follicular lymphoma
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-06-25
Просмотров: 132
Описание:
On June 18, 2025, the Food and Drug Administration (FDA) approved tafasitamab in combination with lenalidomide and rituximab (R-squared) for adult patients with relapsed/refractory (R/R) follicular lymphoma (FL). In this interview, Tycel Phillips, MD, City of Hope, Duarte, CA, comments on the approval and highlights the potential of this combination approach to replace R-squared for the treatment of patients who are heavily pre-treated or relapse early following their prior line of therapy. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![Эффект Джанибекова [Veritasium]](https://imager.clipsaver.ru/N9HlQ-XVnFk/max.jpg)
